Infrared Observations of the Helix Planetary Nebula

We have mapped the Helix (NGC 7293) planetary nebula (PN) with the IRAC instrument on the Spitzer Space Telescope. The Helix is one of the closest bright PNs and therefore provides an opportunity to resolve the small-scale structure in the nebula. The emission from this PN in the 5.8 and 8 μm IRAC bands is dominated by the pure rotational lines of molecular hydrogen, with a smaller contribution from forbidden line emission such as [Ar III] in the ionized region. The IRAC images resolve the "cometary knots," which have been previously studied in this PN. The "tails" of the knots and the radial rays extending into the outer regions of the PN are seen in emission in the IRAC bands. IRS spectra on the main ring and the emission in the IRAC bands are consistent with shock-excited H_2 models, with a small (~10%) component from photodissociation regions. In the northeast arc, the H_2 emission is located in a shell outside the Hα emission

Material Induced Anisotropic Damage

The anisotropy in damage can be driven by two different phenomena; anisotropic defor-mation state named Load Induced Anisotropic Damage (LIAD) and anisotropic (shape and/or distribution) second phase particles named Material Induced Anisotropic Damage (MIAD). Most anisotropic damage models are based on LIAD. This work puts emphasis on the presence of MIAD in DP600 steel. Scanning Electron Microscopic (SEM) analysis was carried out on undeformed and deformed tensile specimens. The martensite morphology showed anisotropy in size and orientation. Consequently, significant MIAD was observed in the deformed tensile specimens. A through thickness shear failure is observed in the tensile specimen, which is pulled along the rolling direction (RD), whereas a dominant ductile fracture is observed when pulled perpendicular to RD. The Modified Lemaitre’s (ML) anisotropic damage model is improved to account for MIAD in a phenomenological manner. The MIAD parameters are determined from tensile tests carried out in 0o, 45o and 90o to the RD. The formability of DP600 is lower in the RD compared to that in 90o to the RD, due to the phenomenon of MIAD

Thermal Phase Variations of WASP-12b: Defying Predictions

[Abridged] We report Warm Spitzer full-orbit phase observations of WASP-12b at 3.6 and 4.5 micron. We are able to measure the transit depths, eclipse depths, thermal and ellipsoidal phase variations at both wavelengths. The large amplitude phase variations, combined with the planet's previously-measured day-side spectral energy distribution, is indicative of non-zero Bond albedo and very poor day-night heat redistribution. The transit depths in the mid-infrared indicate that the atmospheric opacity is greater at 3.6 than at 4.5 micron, in disagreement with model predictions, irrespective of C/O ratio. The secondary eclipse depths are consistent with previous studies. We do not detect ellipsoidal variations at 3.6 micron, but our parameter uncertainties -estimated via prayer-bead Monte Carlo- keep this non-detection consistent with model predictions. At 4.5 micron, on the other hand, we detect ellipsoidal variations that are much stronger than predicted. If interpreted as a geometric effect due to the planet's elongated shape, these variations imply a 3:2 ratio for the planet's longest:shortest axes and a relatively bright day-night terminator. If we instead presume that the 4.5 micron ellipsoidal variations are due to uncorrected systematic noise and we fix the amplitude of the variations to zero, the best fit 4.5 micron transit depth becomes commensurate with the 3.6 micron depth, within the uncertainties. The relative transit depths are then consistent with a Solar composition and short scale height at the terminator. Assuming zero ellipsoidal variations also yields a much deeper 4.5 micron eclipse depth, consistent with a Solar composition and modest temperature inversion. We suggest future observations that could distinguish between these two scenarios.Comment: 19 pages, 10 figures, ApJ in press. Improved discussion of gravity brightenin

Antioxidants for preventing and reducing muscle soreness after exercise

Background Muscle soreness typically occurs after intense exercise, unaccustomed exercise or actions that involve eccentric contractions where the muscle lengthens while under tension. It peaks between 24 and 72 hours after the initial bout of exercise. Many people take antioxidant supplements or antioxidant-enriched foods before and after exercise in the belief that these will prevent or reduce muscle soreness after exercise. Objectives To assess the effects (benefits and harms) of antioxidant supplements and antioxidant-enriched foods for preventing and reducing the severity and duration of delayed onset muscle soreness following exercise. Search methods We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, SPORTDiscus, trial registers, reference lists of articles and conference proceedings up to February 2017. Selection criteria 205 Antioxidants for preventing and reducing muscle soreness after exercise We included randomised and quasi-randomised controlled trials investigating the effects of all forms of antioxidant supplementation including specific antioxidant supplements (e.g. tablets, powders, concentrates) and antioxidant-enriched foods or diets on preventing or reducing delayed onset muscle soreness (DOMS). We excluded studies where antioxidant supplementation was combined with another supplement. Data collection and analysis Two review authors independently screened search results, assessed risk of bias and extracted data from included trials using a pre-piloted form. Where appropriate, we pooled results of comparable trials, generally using the random-effects model. The outcomes selected for presentation in the 'Summary of findings' table were muscle soreness, collected at times up to 6 hours, 24, 48, 72 and 96 hours post-exercise, subjective recovery and adverse effects. We assessed the quality of the evidence using GRADE. Main results Fifty randomised, placebo-controlled trials were included, 12 of which used a cross-over design. Of the 1089 participants, 961 (88.2%) were male and 128 (11.8%) were female. The age range for participants was between 16 and 55 years and training status varied from sedentary to moderately trained. The trials were heterogeneous, including the timing (pre-exercise or post-exercise), frequency, dose, duration and type of antioxidant supplementation, and the type of preceding exercise. All studies used an antioxidant dosage higher than the recommended daily amount. The majority of trials (47) had design features that carried a high risk of bias due to selective reporting and poorly described allocation concealment, potentially limiting the reliability of their findings. We tested only one comparison: antioxidant supplements versus control (placebo). No studies compared high-dose versus low-dose, where the low-dose supplementation was within normal or recommended levels for the antioxidant involved. Pooled results for muscle soreness indicated a small difference in favour of antioxidant supplementation after DOMSinducing exercise at all main follow-ups: up to 6 hours (standardised mean difference (SMD) -0.30, 95% confidence interval (CI) -0.56 to -0.04; 525 participants, 21 studies; low-quality evidence); at 24 hours (SMD -0.13, 95% CI -0.27 to 0.00; 936 participants, 41 studies; moderate-quality evidence); at 48 hours (SMD -0.24, 95% CI -0.42 to -0.07; 1047 participants, 45 studies; low-quality evidence); at 72 hours (SMD -0.19, 95% CI -0.38 to -0.00; 657 participants, 28 studies; moderate-quality evidence), and little difference at 96 hours (SMD -0.05, 95% CI -0.29 to 0.19; 436 participants, 17 studies; low-quality evidence). When we rescaled to a 0 to 10 cm scale in order to quantify the actual difference between groups, we found that the 95% CIs for all five follow-up times were all well below the minimal important difference of 1.4 cm: up to 6 hours (MD -0.52, 95% CI -0.95 to -0.08); at 24 hours (MD -0.17, 95% CI -0.42 to 0.07); at 48 hours (MD -0.41, 95% CI -0.69 to -0.12); at 72 hours (MD -0.29, 95% CI -0.59 to 0.02); and at 96 hours (MD -0.03, 95% CI -0.43 to 0.37). Thus, the effect sizes suggesting less muscle soreness with antioxidant supplementation were very unlikely to equate to meaningful or important differences in practice. Neither of our subgroup analyses to examine for differences in effect according to type of DOMSinducing exercise (mechanical versus whole body aerobic) or according to funding source confirmed subgroup differences. Sensitivity analyses excluding cross-over trials showed that their inclusion had no important impact on results. None of the 50 included trials measured subjective recovery (return to previous activities without signs or symptoms). There is very little evidence regarding the potential adverse effects of taking antioxidant supplements as this outcome was reported in only nine trials (216 participants). From the studies that did report adverse effects, two of the nine trials found adverse effects. All six participants in the antioxidant group of one trial had diarrhoea and four of these also had mild indigestion; these are well-known side effects of the particular antioxidant used in this trial. One of 26 participants in a second trial had mild gastrointestinal distress. Authors' conclusions There is moderate to low-quality evidence that high dose antioxidant supplementation does not result in a clinically relevant reduction of muscle soreness after exercise at up to 6 hours or at 24, 48, 72 and 96 hours after exercise. There is no evidence available on subjective recovery and only limited evidence on the adverse effects of taking antioxidant supplements. The findings of, and messages from, this review provide an opportunity for researchers and other stakeholders to come together and consider what are the priorities, and underlying justifications, for future research in this area

Antioxidants for preventing and reducing muscle soreness after exercise: a Cochrane systematic review

Objective: To determine whether antioxidants supplements and antioxidant-enriched foods can prevent or reduce delayed onset muscle soreness after exercise. Methods: We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, SPORTDiscus, trial registers, reference lists of articles and conference proceedings up to February 2017 Results: In total, 50 studies were included in this review which included a total of 1089 participants (961 were male and 128 were female) with an age range between 16 and 55 years. All studies used an antioxidant dosage higher than the recommended daily amount. The majority of trials (47) had design features that carried a high risk of bias due to selective reporting and poorly described allocation concealment, potentially limiting the reliability of their findings. We rescaled to a 0 to 10 cm scale in order to quantify the actual difference between groups and we found that the 95% CIs for all five follow-up times were all well below the minimal important difference of 1.4 cm: up to 6 hours (MD -0.52, 95% CI -0.95 to -0.08); at 24 hours (MD -0.17, 95% CI -0.42 to 0.07); at 48 hours (MD -0.41, 95% CI -0.69 to -0.12); at 72 hours (MD -0.29, 95% CI -0.59 to 0.02); and at 96 hours (MD -0.03, 95% CI - 0.43 to 0.37). Thus, the effect sizes suggesting less muscle soreness with antioxidant supplementation were very unlikely to equate to meaningful or important differences in practice. Conclusions: There is moderate to low-quality evidence that high dose antioxidant supplementation does not result in a clinically relevant reduction of muscle soreness after exercise at up to 6 hours or at 24, 48, 72 and 96 hours after exercise. There is no evidence available on subjective recovery and only limited evidence on the adverse effects of taking antioxidant supplements

Radial Bargmann representation for the Fock space of type B

Let $\nu_{\alpha,q}$ be the probability and orthogonality measure for the $q$-Meixner-Pollaczek orthogonal polynomials, which has appeared in \cite{BEH15} as the distribution of the $(\alpha,q)$-Gaussian process (the Gaussian process of type B) over the $(\alpha,q)$-Fock space (the Fock space of type B). The main purpose of this paper is to find the radial Bargmann representation of $\nu_{\alpha,q}$. Our main results cover not only the representation of $q$-Gaussian distribution by \cite{LM95}, but also of $q^2$-Gaussian and symmetric free Meixner distributions on $\mathbb R$. In addition, non-trivial commutation relations satisfied by $(\alpha,q)$-operators are presented.Comment: 13 pages, minor changes have been mad